Search Results

Active, not yet recruiting    Who can join   

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Active, currently enrolling    Who can join   

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma

Keywords: Unresectable Melanoma; Metastatic Melanoma; Advanced Melanoma; Stage III; Stage…
Study Type: INTERVENTIONAL   |  Region: Northwest

---

Active, currently enrolling    Who can join   

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

Keywords: Loncastuximab Tesirine; Refractory Diffuse Large B-Cell Lymphoma; Relapsed…
Study Type: INTERVENTIONAL   |  Region: Northwest

---

Active, currently enrolling    Who can join   

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III (S1501)

Keywords: Oncology (Adult); S1501; Breast Neoplasms; Neoplasms; Cardiotoxicity; Neoplasms…
Study Type: INTERVENTIONAL   |  Region: Northwest

---

Active, not yet recruiting    Who can join   

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Active, not yet recruiting    Who can join   

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Active, not yet recruiting    Who can join   

A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Active, currently enrolling    Who can join   

A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Enrollment complete    Who can join   

AstraZeneca ADAURA D5164C00001: A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Active, enrolling only by invitation    Who can join   

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---